Key statistics dashboard for Nuvectis Pharma, Inc. (NVCT). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases.
Stock Data
| Price | $21.87 |
| Market Cap | $580M |
| Enterprise Value | $559.5M |
| Beta | -0.21 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -16.50 |
| Price / Book | 55.89 |
| P/S | 0.00 |
| EV/EBITDA | -19.35 |
| EV/Sales | 0.00 |
| EV/FCF | -28.68 |
| P/FCF | -29.41 |
| Earnings Yield | -5.41% |
| FCF Yield | -3.35% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -169.47% |
| Return on Assets | -124.45% |
| Return on Invested Capital | -317.86% |
| Return on Capital Employed | -317.86% |
Financial Health
| Current Ratio | 1.68 |
| Quick Ratio | 1.68 |
| Cash Ratio | 1.67 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Net Debt / EBITDA | 0.77 |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 0.39 |
| Cash per share | 0.94 |
| FCF per share | -0.83 |
| Tangible Book Value per share | 0.39 |
| Dividend per share | 0.00 |
Related companies: ARMP · CGEN · CRDF · CYBN · IPHA · MIST · MOLN
Explore sector: Healthcare · Biotechnology
More sections of NVCT: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks